Evofem Biosciences, Inc. (EVFM) financial statements (2021 and earlier)

Company profile

Business Address 12400 HIGH BLUFF DRIVE
SAN DIEGO, CA 92130
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4916131138
Cash and cash equivalents4916131138
Restricted cash and investments2300   
Receivables1     
Inventory, net of allowances, customer advances and progress billings7     
Inventory7     
Other undisclosed current assets18111112
Total current assets:9826241340
Noncurrent Assets
Operating lease, right-of-use asset7 
Property, plant and equipment401 00
Restricted cash and investments   0  
Other noncurrent assets111   
Other undisclosed noncurrent assets 0  00
Total noncurrent assets:1222000
TOTAL ASSETS:11028441340
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities221223115
Accounts payable1169114
Accrued liabilities4312101
Employee-related liabilities743   
Debt52 4  3
Other liabilities1     
Other undisclosed current liabilities20  01
Total current liabilities:771327119
Noncurrent Liabilities
Long-term debt and lease obligation31    7
Long-term debt, excluding current maturities25    7
Operating lease, liability6 
Liabilities, other than long-term debt  0   
Deferred revenue and credits0   
Other undisclosed noncurrent liabilities(6)     
Total noncurrent liabilities:31 0  7
Total liabilities:10913271116
Stockholders' equity
Stockholders' equity attributable to parent116(23)31224
Common stock000000
Additional paid in capital657529410139138137
Accumulated deficit(655)(513)(433)(136)(126)(113)
Total stockholders' equity:116(23)31224
TOTAL LIABILITIES AND EQUITY:11028441340

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues0     
Cost of revenue
(Cost of Goods and Services Sold)
(0)     
Gross profit:(0)     
Operating expenses (53)(78)(10)(12)(42)
Other undisclosed operating loss(104)     
Operating loss:(104)(53)(78)(10)(12)(42)
Nonoperating income (expense)(39)(27)(48)000
Investment income, nonoperating000000
Interest and debt expense(2)   (1)(1)
Other undisclosed income from continuing operations before equity method investments, income taxes2     
Loss from continuing operations before income taxes:(142)(80)(126)(10)(13)(43)
Income tax expense(0)(0)(0)   
Net loss attributable to parent:(142)(80)(126)(10)(13)(43)
Preferred stock dividends and other adjustments  (0)   
Net loss available to common stockholders, diluted:(142)(80)(126)(10)(13)(43)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(142)(80)(126)(10)(13)(43)
Comprehensive loss, net of tax, attributable to parent:(142)(80)(126)(10)(13)(43)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: